Sequoia Financial Advisors LLC grew its stake in shares of Altimmune, Inc. (NASDAQ:ALT – Free Report) by 34.5% in the fourth ...

Altimmune (NASDAQ:ALT – Get Free Report)‘s stock had its “buy” rating reiterated by analysts at HC Wainwright in a research ...

We recently shared a list of 10 Best Short Squeeze Stocks To Buy According to Analysts. In this article, we will see how ...

Shares of Altimmune Inc. are down more than 23% this year, but that has not deterred retail investors from losing hope in the ...

Explore the promising potential of Altimmune, Inc.'s Pemvidutide in NASH, AUD, & obesity treatment, with key trials underway.

Bullish option flow detected in Altimmune (ALT) with 8,561 calls trading, 3x expected, and implied vol increasing almost 4 points to 114.21%.

The company unveiled plans last week to test its GLP-1/glucagon dual receptor agonist in alcohol use disorder and ...

Evercore ISI likes the expansion of pemvidutide into alcohol liver disease and alcohol use disorder as it adds another leg to the pemvidutide ...

The Maryland-based biopharma joins Eli Lilly and Novo Nordisk in trialing a GLP-1 agonist for alcohol- and liver-related ...

Altimmune plans Phase 2 trials in 2025 for pemvidutide in alcohol use disorder and liver disease, highlighting weight loss ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Altimmune said on Thursday that it plans to test its lead experimental obesity drug, pemvidutide, to potentially treat alcohol use disorder and alcohol-associated liver disease.